Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
Revenue Growth %: +36.2%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +36.2%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.38 million versus the consensus estimate of $25.6 million.
Halozyme Therapeutics sees FY2015 EPS of $85.00-$95.00, versus the consensus of $97.70.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
